Summary: Creatine is widely known as a popular gym supplement sold in tubs to support muscle growth and athletic performance. Because the brain and skeletal muscle share similar cellular bioenergetics, scientists have increasingly asked whether creatine’s ability to boost cellular energy could also help treat mood disorders such as depression.
A new systematic review rigorously examined the clinical evidence to answer a central question: can creatine serve as an effective treatment for depression?
Key Facts
- The Neuroenergetic Hypothesis: The brain is metabolically demanding, consuming a large portion of the body’s energy despite its small size. Mood disorders have been associated with altered creatine metabolism and impaired cellular energy production, making restoration of adenosine triphosphate (ATP) via creatine a plausible therapeutic target.
- Positive Signals: Two trials, both from the same study of women with major depressive disorder, found that adding 5 g of creatine daily to the antidepressant escitalopram produced a substantial reduction in depressive symptoms compared with placebo, with a large effect size (Cohen’s d = 1.13). Another trial reported a steeper symptom reduction when creatine was combined with cognitive behavioral therapy (CBT).
- Null Findings: Three other trials reported no clinical benefit. Creatine did not alleviate symptoms in patients who were already treatment-resistant to standard medications, produced no statistically significant effect in adolescent girls, and showed no benefit for depressive episodes in bipolar disorder.
- Bipolar Mania Warning: Two individuals with bipolar disorder who received creatine developed hypomania or mania during the trial. This important safety signal highlights that modifying cellular energy pathways can produce severe adverse events in certain psychiatric contexts.
- Sex-Dependent Clue: Preclinical animal research suggests creatine alters depression-like behavior differently in male and female rodents. This sex-dependent effect may help explain why trials enrolling only women reported the most positive clinical results.
- Safety and Tolerability: Aside from the bipolar mania signal, creatine demonstrated a strong safety profile across studies, with adverse events largely limited to mild gastrointestinal discomfort.
Source: Genomic Press
Most people recognize creatine from the gym supplement aisle, prized for increasing strength and lean muscle. Less widely known is that the biochemical role creatine plays in muscle energy also applies to the brain. If creatine helps replenish cellular energy, it might theoretically improve brain function and mood as well as muscle performance.
A systematic review published in Brain Medicine evaluated clinical trials to determine whether creatine supplementation can meaningfully reduce depressive symptoms.
What the Researchers Reviewed
The review team, led by Bassam Jeryous Fares of the University of Ottawa, did not conduct new clinical trials. Instead, they identified and evaluated existing randomized controlled trials. After screening the literature, they included six published reports representing five randomized, double-blind, placebo-controlled trials.
Those trials took place across five countries—South Korea, the United States, Brazil, Israel, and India—and together enrolled 238 participants at baseline: 126 assigned to creatine and 112 to placebo. The average participant age was 36, and most participants were women; two trials enrolled women only.
Four trials targeted major depressive disorder and one enrolled people with bipolar disorder who were experiencing a depressive episode. Because the studies varied substantially in design, dosing, populations, and outcomes, the reviewers summarized results narratively rather than pooling them into a single meta-analytic statistic.
A Split Decision
The evidence was mixed. Two of the five randomized trials, both from the same female-only study, reported clear benefit: adding 5 g of creatine daily to escitalopram led to a larger symptom reduction after eight weeks than escitalopram plus placebo, with a large effect size on the Hamilton Depression Rating Scale and higher remission rates. A separate trial combining creatine with cognitive behavioral therapy also saw a greater symptom decline than therapy plus placebo.
Conversely, three trials reported no measurable benefit. Creatine at 5 or 10 g daily did not help individuals who had already failed to respond to medication. A dose-ranging study in adolescent girls showed no advantage over placebo. In the bipolar depression trial, creatine provided no treatment benefit—and two patients taking creatine developed hypomania or mania, underscoring a significant safety concern for that population.
Why Creatine Could Affect Mood
The rationale behind these studies is biologically grounded. The brain requires substantial energy to maintain neuronal activity, and ATP is the primary cellular energy currency. Creatine supports rapid regeneration of ATP, so supplementation could theoretically improve cellular energy in brain regions implicated in depression. Studies have identified altered creatine metabolism and impaired energy production in the brains of some people with mood disorders, leading researchers to test whether boosting brain energetics might relieve depressive symptoms.
Creatine may also influence neurotransmitter systems such as dopamine and serotonin, which are central to many antidepressant treatments. The reviewers, however, stress that current evidence is correlational rather than proof of causation: depression’s biology is complex, and energy metabolism is only one piece of the puzzle.
“The signal is interesting, but it is not a verdict,” said Bassam Jeryous Fares. “Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration.”
Nicholas Fabiano, corresponding author, described the review as a starting point. “Creatine appears safe for most people; adverse events in these studies were generally mild gastrointestinal symptoms. We still cannot say reliably that creatine reduces depressive symptoms across diverse patient groups.”
What’s Needed Next
The authors emphasize limitations of the existing trials: small sample sizes, uneven sex representation, variable study quality, and short durations (often eight weeks). Two trials were judged to have low risk of bias while three raised some concerns related to randomization and handling of missing data. Given these constraints, findings are not yet generalizable.
The reviewers call for larger, longer, higher-quality randomized trials. Future studies should examine creatine in combination with exercise, explore dose–response relationships, and investigate sex-specific effects suggested by animal research. For now, creatine remains a promising lead rather than an established antidepressant: the molecule that supports muscle energy deserves further careful study in the context of brain health.
Key Questions Answered:
A: Creatine helps cells rapidly regenerate adenosine triphosphate (ATP), the molecular currency used to power cellular processes. The brain is an energy-intensive organ, and studies have found altered creatine metabolism and impaired energy production in some people with depression. By boosting cellular energy capacity, creatine could theoretically support neuronal function and improve mood, although current human data remain preliminary and correlational.
A: Depression is heterogeneous, and response to interventions can vary by age, sex, hormonal status, illness severity, and treatment history. In the reviewed trials, creatine appeared most effective in adult women when added to an antidepressant, but it failed in treatment-resistant adults, adolescents, and in bipolar depression. Animal studies also show sex-specific effects, suggesting biological differences may influence outcomes.
A: For most people, creatine is well tolerated and side effects are usually limited to mild gastrointestinal discomfort. However, the review identified a serious safety signal in bipolar disorder: two patients developed hypomania or mania after taking creatine. Anyone with a diagnosed mood disorder should consult their psychiatrist or healthcare provider before starting creatine, and bipolar patients should avoid unsupervised use due to mania risk.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by the editorial staff.
About this depression research news
Author: Ma-Li Wong (email: [email protected])
Source: Genomic Press
Contact: Ma-Li Wong – Genomic Press
Image: The image is credited to Neuroscience News
Original Research: The findings are reported in Brain Medicine.